Humana (HUM) stock
Health Care · Managed Health Care
Humana (HUM) is a Managed Health Care company in the Health Care sector, headquartered in Louisville, Kentucky. As of October 23, 2026, HUM closed at $422.07, a market capitalization of $50.68 billion, the 231st largest company in the S&P 500. Over the last twelve months it generated $145.68 billion in revenue (+26% year over year) and $1.95 billion in free cash flow. The stock trades at 39.9x trailing earnings and 24.7x forward earnings.
- 1-year total return: +46.5% (dividends reinvested)
- 5-year return: -0.8% a year
- 52-week range: $163.11 – $456.50
- Gross margin 13.7%, operating margin 3.5%
- Dividend yield: 0.84%
- FI Handbook report card: C across 10 metrics
- 30th largest of 60 Health Care stocks in the S&P 500
HUM price chart
1Y price change: +44.9% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| HUM | +12.6% | +66.0% | +46.5% | -5.4% | -0.8% | +10.1% | +12.8% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1981.
HUM key statistics
- Market cap
- $50.7B
- #231 in S&P 500
- P/E (TTM)
- 39.9x
- Forward P/E
- 24.7x
- EPS (TTM)
- $10.58
- Revenue (TTM)
- $145.7B
- +26%
- Free cash flow
- $1.9B
- Gross margin
- 13.7%
- Operating margin
- 3.5%
- Return on equity
- 6.9%
- Dividend yield
- 0.84%
- 52-week range
- $163.11 – $456.50
- Beta
- 0.74
- Price / sales
- 0.3x
- EV / EBITDA
- 11.6x
- Debt / equity
- 0.76x
- Employees
- 67,060
HUM report card
CTen fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth26.2%A
- Gross margin13.7%F
- Operating margin3.5%D
- FCF margin1.3%D
- Return on equity6.9%D
- Net debt / EBITDA-2.5xA
- Forward P/E24.7xC
- PEG ratio1.4xB
- Shareholder yield1.1%D
- Share count change / yr-1.9%B
Humana financials
Revenue went from $54.4B in fiscal 2016 to $129.7B in fiscal 2025, growing 10.1% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.4B | $53.8B | $56.9B | $64.9B | $77.2B | $83.1B | $92.9B | $106.4B | $117.8B | $129.7B |
| Operating income | $1.7B | $4.3B | $3.1B | $3.2B | $5.0B | $3.1B | $3.8B | $4.0B | $2.6B | $2.7B |
| Net income | $614.0M | $2.4B | $1.7B | $2.7B | $3.4B | $2.9B | $2.8B | $2.5B | $1.2B | $1.2B |
| EPS (diluted) | $4.07 | $16.81 | $12.16 | $20.10 | $25.31 | $22.67 | $22.08 | $20.00 | $9.98 | $9.84 |
| Free cash flow | $1.4B | $3.5B | $1.6B | $4.5B | $4.7B | $920.0M | $3.5B | $3.0B | $2.4B | $375.0M |
| Buybacks | $104.0M | $3.4B | $1.1B | $1.1B | $1.8B | $79.0M | $2.1B | $1.6B | $817.0M | $151.0M |
| Dividends paid | $177.0M | $220.0M | $265.0M | $291.0M | $323.0M | $354.0M | $392.0M | $431.0M | $431.0M | $430.0M |
| Diluted shares | 150.9M | 145.6M | 138.4M | 134.7M | 133.0M | 129.4M | 127.1M | 124.4M | 120.9M | 120.8M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into HUM?
A reverse DCF asks what growth the current price requires. With an enterprise value of $41.6B and $1.9B of trailing free cash flow, Humana needs to grow free cash flow about 12.2% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew -39.6% a year over the last five years.
P/E ratio history
Current 42.9x vs. median 18.1x (10th–90th percentile 8.4x–27.8x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
HUM dividend
- Dividend yield
- 0.84%
- Annual dividend
- $3.54
- Years of increases
- —
- 5-yr dividend growth
- 7.2%
- per year
- Payout ratio
- 33%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
HUM analyst price targets
24 analysts' average 12-month target is $465.13 (+10% vs. $422.07). Targets range from $280.00 to $596.00. 62% rate it a buy.
HUM earnings
Next report: November 6, 2026. Humana has beaten EPS estimates 6 quarters in a row. Last quarter's revenue was $40.9B (+26% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 29, 2026 | $7.00 | $7.61 | +8.8% |
| Apr 29, 2026 | $10.20 | $10.31 | +1.1% |
| Feb 11, 2026 | $-3.99 | $-3.96 | +0.7% |
| Nov 5, 2025 | $2.83 | $3.24 | +14.6% |
| Jul 29, 2025 | $5.87 | $6.27 | +6.9% |
| Apr 30, 2025 | $10.07 | $11.58 | +15.0% |
| Feb 11, 2025 | $-2.12 | $-2.16 | -1.9% |
| Oct 30, 2024 | $3.39 | $4.16 | +22.9% |
Stocks like HUM
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
 ELV Elevance Health | -1.20% | +30% | $95.4B | 18.7x | Compare |
 CNC Centene | -1.50% | +104% | $34.7B | — | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 MRK Merck & | -1.34% | +72% | $358.4B | 117.2x | Compare |
 TMO Thermo Fisher Scientific | -0.40% | +18% | $249.1B | 35.5x | Compare |
HUM news
- Humana (OM:HUM) Q3 Results Confront A Persistent Margin Squeeze · Oct 23, 2026
- Humana Gains From Premium Growth Despite Rising Benefit Costs · Oct 21, 2026
- Humana (HUM) Recasts CenterWell Clinics With New Joint Venture And Fresh Capital · Oct 21, 2026
- TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand · Oct 20, 2026
- What Healthcare Services Group (HCSG) Said on Its Q3 Earnings Call · Oct 21, 2026
HUM stock FAQ
What is HUM's market cap?
Humana's market capitalization is $50.68 billion as of October 23, 2026, ranking 231st in the S&P 500.
What is HUM's P/E ratio?
HUM trades at a trailing price-to-earnings ratio of 39.9x and a forward P/E of 24.7x. Its median P/E over the period we track is 18.1x.
Does HUM pay a dividend?
Yes. Humana pays $3.54 per share a year, a 0.84% yield. Dividends grew 7.2% a year over the last five years.
How much has HUM stock returned?
Including reinvested dividends, HUM returned +46.5% over one year, -0.8% a year over five years, +10.1% a year over ten years through October 23, 2026.
Is HUM stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Humana must grow free cash flow about 12% a year for the next decade. Its free cash flow fell 40% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the HUM price target?
24 analysts cover HUM with an average 12-month price target of $465.12, +10% from the current price. 62% of them rate it a buy.
When does HUM report earnings?
Humana is expected to report earnings on November 6, 2026. It has beaten EPS estimates 6 quarters in a row.
How many employees does Humana have?
Humana has about 67,060 full-time employees, or $2.2 million of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology